189 related articles for article (PubMed ID: 21926486)
1. Milnacipran in panic disorder with agoraphobia and major depressive disorder: a case report.
Chen MH; Liou YJ
Clin Neuropharmacol; 2011; 34(5):201-2. PubMed ID: 21926486
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of milnacipran in panic disorder: an open trial.
Blaya C; Seganfredo AC; Dornelles M; Torres M; Paludo A; Heldt E; Manfro GG
Int Clin Psychopharmacol; 2007 May; 22(3):153-8. PubMed ID: 17414741
[TBL] [Abstract][Full Text] [Related]
3. Facing the fear--clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia.
Liebscher C; Wittmann A; Gechter J; Schlagenhauf F; Lueken U; Plag J; Straube B; Pfleiderer B; Fehm L; Gerlach AL; Kircher T; Fydrich T; Deckert J; Wittchen HU; Heinz A; Arolt V; Ströhle A
Eur Neuropsychopharmacol; 2016 Mar; 26(3):431-44. PubMed ID: 26837851
[TBL] [Abstract][Full Text] [Related]
4. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia.
Fava GA; Bernardi M; Tomba E; Rafanelli C
Int J Neuropsychopharmacol; 2007 Dec; 10(6):835-8. PubMed ID: 17224089
[TBL] [Abstract][Full Text] [Related]
5. Sustained Resolution of Panic Disorder, Agoraphobia, and Generalized Anxiety Disorder With a Single Ketamine Infusion: A Case Report.
Ray SM; Kious BM
Prim Care Companion CNS Disord; 2016 Jul; 18(4):. PubMed ID: 27828703
[No Abstract] [Full Text] [Related]
6. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder.
Dannon PN; Iancu I; Lowengrub K; Gonopolsky Y; Musin E; Grunhaus L; Kotler M
Clin Neuropharmacol; 2007; 30(6):326-34. PubMed ID: 18090457
[TBL] [Abstract][Full Text] [Related]
7. Remarkable effect of milnacipran in the treatment of Japanese major depressive patients.
Higuchi H; Yoshida K; Takahashi H; Naito S; Tsukamoto K; Kamata M; Ito K; Sato K; Shimizu T
Hum Psychopharmacol; 2002 Jun; 17(4):195-6. PubMed ID: 12404688
[No Abstract] [Full Text] [Related]
8. Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report.
Kijima R; Tesen H; Igata R; Okamoto N; Yoshimura R
BMC Psychiatry; 2023 Oct; 23(1):787. PubMed ID: 37891534
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: treatment results through 1-year follow-up.
van Apeldoorn FJ; Timmerman ME; Mersch PP; van Hout WJ; Visser S; van Dyck R; den Boer JA
J Clin Psychiatry; 2010 May; 71(5):574-86. PubMed ID: 20492852
[TBL] [Abstract][Full Text] [Related]
10. Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia.
Bakker A; van Balkom AJ; van Dyck R
Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S25-30. PubMed ID: 11110016
[TBL] [Abstract][Full Text] [Related]
11. Milnacipran affects mouse impulsive, aggressive, and depressive-like behaviors in a distinct dose-dependent manner.
Tsutsui-Kimura I; Ohmura Y; Yoshida T; Yoshioka M
J Pharmacol Sci; 2017 Jul; 134(3):181-189. PubMed ID: 28694090
[TBL] [Abstract][Full Text] [Related]
12. Influence of painful physical symptoms in the treatment of Japanese patients with melancholic major depressive disorder: A prospective cohort study.
Sekine A; Hozumi S; Shimizu T
Psychiatry Res; 2016 Aug; 242():240-244. PubMed ID: 27294798
[TBL] [Abstract][Full Text] [Related]
13. Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication.
Uhlenhuth EH; Matuzas W; Warner TD; Paine S; Lydiard RB; Pollack MH
J Clin Psychopharmacol; 2000 Dec; 20(6):622-7. PubMed ID: 11106133
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease.
Mizukami K; Hatanaka K; Tanaka Y; Sato S; Asada T
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):349-52. PubMed ID: 19166899
[TBL] [Abstract][Full Text] [Related]
15. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.
Tignol J; Pujol-Domenech J; Chartres JP; Léger JM; Plétan Y; Tonelli I; Tournoux A; Pezous N
Acta Psychiatr Scand; 1998 Feb; 97(2):157-65. PubMed ID: 9517912
[TBL] [Abstract][Full Text] [Related]
16. Rate of improvement during and across three treatments for panic disorder with or without agoraphobia: cognitive behavioral therapy, selective serotonin reuptake inhibitor or both combined.
Van Apeldoorn FJ; Van Hout WJ; Timmerman ME; Mersch PP; den Boer JA
J Affect Disord; 2013 Sep; 150(2):313-9. PubMed ID: 23676529
[TBL] [Abstract][Full Text] [Related]
17. Improvement of selective serotonin reuptake inhibitor-induced sexual dysfunction without worsening of depressive symptom after switching to milnacipran.
Takahashi H; Ishigooka J
Clin Neuropharmacol; 2009; 32(3):177-8. PubMed ID: 19483494
[No Abstract] [Full Text] [Related]
18. Personality traits in early phases of panic disorder: implications on the presence of agoraphobia, clinical severity and short-term outcome.
Carrera M; Herrán A; Ramírez ML; Ayestarán A; Sierra-Biddle D; Hoyuela F; Rodríguez-Cabo B; Vázquez-Barquero JL
Acta Psychiatr Scand; 2006 Dec; 114(6):417-25. PubMed ID: 17087790
[TBL] [Abstract][Full Text] [Related]
19. Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor.
Preskorn SH
J Psychiatr Pract; 2004 Mar; 10(2):119-26. PubMed ID: 15330407
[No Abstract] [Full Text] [Related]
20. Sertraline treatment of panic disorder: response in patients at risk for poor outcome.
Pollack MH; Rapaport MH; Clary CM; Mardekian J; Wolkow R
J Clin Psychiatry; 2000 Dec; 61(12):922-7. PubMed ID: 11206597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
